<![CDATA[Pharma — Februar 2025]]>Lundbeck OVERBLIK Q4: Omsætning skuffer let men nyeste lægemiddel fortsætter vækst https://proinvestor.com/investornyt/1274030/lundbeck-overblik-q4-omsaetning-skuffer-let-men-nyeste-laegemiddel-fortsaetter-vaekst

]]>https://dev.proinvestor.com/forum/topic/400895/pharma-februar-2025RSS for NodeSun, 07 Jun 2026 08:36:06 GMTWed, 05 Feb 2025 06:57:05 GMT60<![CDATA[Reply to Pharma — Februar 2025 on Fri, 28 Feb 2025 04:59:25 GMT]]>ALK får godkendt behandling til yngre børn af amerikanske sundhedsmyndigheder https://proinvestor.com/investornyt/1284667/alk-far-godkendt-behandling-til-yngre-born-af-amerikanske-sundhedsmyndigheder

]]>https://dev.proinvestor.com/forum/post/8038224https://dev.proinvestor.com/forum/post/8038224Fri, 28 Feb 2025 04:59:25 GMT<![CDATA[Reply to Pharma — Februar 2025 on Wed, 19 Feb 2025 11:10:37 GMT]]>ALK's topchef om toldtrussel: Det er i småtingsafdelingen for os https://proinvestor.com/investornyt/1280154/alks-topchef-om-toldtrussel-det-er-i-smatingsafdelingen-for-os

]]>https://dev.proinvestor.com/forum/post/8038223https://dev.proinvestor.com/forum/post/8038223Wed, 19 Feb 2025 11:10:37 GMT<![CDATA[Reply to Pharma — Februar 2025 on Wed, 19 Feb 2025 11:08:39 GMT]]>ALK's topchef om regnskabstal: Europæiske tabletsalg fortsætter frem - har haft mindre skuffelse i USA https://proinvestor.com/investornyt/1280132/alks-topchef-om-regnskabstal-europaeiske-tabletsalg-fortsaetter-frem-har-haft-mindre-skuffelse-i-usa

]]>https://dev.proinvestor.com/forum/post/8038220https://dev.proinvestor.com/forum/post/8038220Wed, 19 Feb 2025 11:08:39 GMT<![CDATA[Reply to Pharma — Februar 2025 on Tue, 18 Feb 2025 10:15:25 GMT]]>
Wrong Link

favicon

(u8829140.ct.sendgrid.net)

]]>https://dev.proinvestor.com/forum/post/8038221https://dev.proinvestor.com/forum/post/8038221Tue, 18 Feb 2025 10:15:25 GMT<![CDATA[Reply to Pharma — Februar 2025 on Tue, 18 Feb 2025 10:14:44 GMT]]>Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept). Teva stiger 7% i formarkedet.

]]>https://dev.proinvestor.com/forum/post/8038222https://dev.proinvestor.com/forum/post/8038222Tue, 18 Feb 2025 10:14:44 GMT<![CDATA[Reply to Pharma — Februar 2025 on Mon, 17 Feb 2025 14:59:51 GMT]]>Over halvdelen af ansøgninger om nye lægemidler handler om kræftmedicin https://www.dr.dk/nyheder/seneste/over-halvdelen-af-ansoegninger-om-nye-laegemidler-handler-om-kraeftmedicin

]]>https://dev.proinvestor.com/forum/post/8038227https://dev.proinvestor.com/forum/post/8038227Mon, 17 Feb 2025 14:59:51 GMT<![CDATA[Reply to Pharma — Februar 2025 on Wed, 12 Feb 2025 10:09:27 GMT]]>Lundbeck får tildelt hastebehandling af middel mod MSA i USA https://proinvestor.com/investornyt/1277195/lundbeck-far-tildelt-hastebehandling-af-middel-mod-msa-i-usa

]]>https://dev.proinvestor.com/forum/post/8038226https://dev.proinvestor.com/forum/post/8038226Wed, 12 Feb 2025 10:09:27 GMT<![CDATA[Reply to Pharma — Februar 2025 on Wed, 05 Feb 2025 07:52:57 GMT]]>Lundbeck sigter efter vækst fra driften på 5-11 pct. i 2025 - opkøb gør indhug https://proinvestor.com/investornyt/1274044/lundbeck-sigter-efter-vaekst-fra-driften-pa-5-11-pct-i-2025-opkob-gor-indhug

]]>https://dev.proinvestor.com/forum/post/8038225https://dev.proinvestor.com/forum/post/8038225Wed, 05 Feb 2025 07:52:57 GMT